Results 161 to 170 of about 277,930 (211)

Selection of radionuclide(s) for targeted alpha therapy based on their nuclear decay properties. [PDF]

open access: yesNucl Med Commun
Ree SM   +6 more
europepmc   +1 more source

Modeling Early Metastatic Progression in Breast Cancer Using a Barrier‐Free, Perfusable Spheroid‐on‐a‐Chip Platform

open access: yesAdvanced Healthcare Materials, EarlyView.
Open‐port, barrier‐free microfluidic device for modeling early metastatic progression. A centrally positioned tumor spheroid releases invasive cells that migrate through the surrounding matrix and intravasate into endothelialized lateral channels.
Vira Sharko   +7 more
wiley   +1 more source

Establishment of a Responsive Tooth‐on‐a‐Chip Platform for the Assessment of Regenerative Factors in Dental Tissue Regeneration

open access: yesAdvanced Healthcare Materials, EarlyView.
Using a tooth‐on‐a‐chip model that recreates interactions between dental epithelial and mesenchymal cells, the authors show that sequential FGF10+BMP4, BMP2, and Emdogain produce distinct, biologically consistent regenerative responses. The platform recapitulates known signal‐specific effects and, for the first time, reveals an influence of Emdogain on
Chong Huang   +3 more
wiley   +1 more source

Artemisinin‐Loaded Core‐Shell Microspheres Modulate Histone Lactylation to Remodel the Microenvironment for Cartilage Protection in Rheumatoid Arthritis

open access: yesAdvanced Healthcare Materials, EarlyView.
ART@PLGA@GH‐A microspheres are developed via microfluidic technology for intra‐articular delivery of artemisinin. The system remodels rheumatoid arthritis microenvironments by regulating metabolic and inflammatory disorders, reducing lactate‐driven histone lactylation and cellular senescence, while restoring cartilage homeostasis and protecting joint ...
Shijie Meng   +10 more
wiley   +1 more source

Advances in Bio‐Integrated Edge Computing Systems for Smart and Connected Health

open access: yesAdvanced Materials, EarlyView.
This review explores advances in bio‐integrated edge computing for healthcare, focusing on co‐designing computing, sensing, and energy strategies to overcome integration and power challenges for optimized, decentralized operation. ABSTRACT Recent advances in bio‐integrated healthcare technologies have enabled continuous, high‐resolution monitoring and ...
Gyuwon Kim   +4 more
wiley   +1 more source

Bacteria‐Trained, MnO2‐Armored Dendritic Cells for Immunotherapy

open access: yesAdvanced Materials, EarlyView.
MnO2‐armored, bacteria‐trained dendritic cells undergo tumor‐responsive mechanical and immunological transformation. The nanocoating masks immune ligands and maintains a mechanically stiff, quiescent state during circulation, while the tumor microenvironment removes the armor and restores cellular deformability and immune accessibility.
Zhao Guo   +9 more
wiley   +1 more source

Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer. [PDF]

open access: yesInt J Mol Sci
Watabe T   +14 more
europepmc   +1 more source

Alpha-Particles for Targeted Therapy

Advanced Drug Delivery Reviews, 2008
Alpha-particles are helium nuclei that deposit DNA damaging energy along their track that is 100 to 1000 times greater than that of conventionally used beta-particle emitting radionuclides for targeted therapy; the damage caused by alpha-particles is predominately double-stranded DNA breaks severe enough so as to be almost completely irreparable.
George Sgouros
exaly   +3 more sources

Advances in Targeted Alpha Therapy for Prostate Cancer [PDF]

open access: yesAnnals of Oncology, 2019
Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity. In this review, we discuss the history, progress, and future potential of TαT in the treatment of prostate cancer, including
Joe O'Sullivan   +2 more
exaly   +7 more sources

Home - About - Disclaimer - Privacy